CRTC1 and breast carcinoma: In a phase 2a randomized, placebo‐controlled clinical trial, dactolisib plus RAD001 selectively inhibited TORC1 downstream of mTOR, with good (decrease in the rate of infections) and safe response.[27] Many clinical trials have been performed to investigate its effects in the treatment of malignancies, including advanced renal cell carcinoma (NCT01453595), metastatic or unresectable malignant PEComa (NCT01690871), advanced solid tumors (NCT01343498), and advanced breast cancer (NCT00620594).